Cantargia

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Equities

Equities by Sector

Sectors

Thematics

Latest

MediaWatch – A two-tier story

Inside the mind of the investor: Mutares

Edison explains: DDoS attacks – destructive by design

Audiovisual

Latest

Uncovering Trusts – Law Debenture Corporation – A unique combination of an ‘multi-cap’ investment portfolio and independent professional services

bp – equity proposition

Percheron Therapeutics – executive interview

About Edison

About Edison

Careers

Cantargia (OMX: CANTA)

Latest Insights

Cantargia (OMX: CANTA) granted new US patent

Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka

Cantargia (OMX: CANTA) – Nadunolimab receives FDA Fast Track designation

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Sector

Equity Analyst

Key Management

Cantargia — CAN04 progressing on all fronts

Cantargia — Useful insights from CANOPY-1 data

Cantargia – executive interview

Cantargia: Edison Open House Healthcare 2022

Cantargia — ‘Post-Novartis’ era has begun

Cantargia – executive interview

Cantargia — Sentiment affected, but fundamentals robust

Cantargia – executive interview

Cantargia — Novartis’s CANOPY-2 trial disappoints

Cantargia – Edison Open House interview

Cantargia — Buoyant on CANFOUR and CANOPY interims

Cantargia — Great equity story underpins large share issue

Executive interview – Cantargia

Cantargia — Excellent end to the year

Cantargia — CANFOUR study on track, US trial preparations

Cantargia — Full Phase I data presented at ASCO

Cantargia — Signs of growing interest in IL-1 pathway targets

Executive interview – Cantargia

Cantargia — Nidanilimab transitioning to Phase IIa

Cantargia — CANFOUR interim Phase I presented at ESMO

Cantargia — Phase IIa set to start in Q418

Cantargia — Tackling tumour promoting inflammation